Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Dong, Qiaofeng; Li, Guosheng; Fozza, Claudio; Wang, Shuli; Shuhuan, Yang; Sang, Yuqi; Liu, Xinguang; Chen, Chunyan

doi:10.1155/2020/7023168

Cited by 12 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past 10 years it has been well established that amount/percentage of regulatory T cells is increased in both chronic and acute myeloid leukemia. Percentage of Treg (identified as CD25hi CD127lo cells) among T cells is increased in peripheral blood (PB) of AML patients [ 166 , 167 ]. CD25hi Treg from PB had increased suppressive activity and expression of molecules such as glucocorticoid-induced TNFR-related protein (GITR), CTLA-4 and granzyme B, but not CCR4 (C-C chemokine receptor type 4), CD39 and CD73 [ 167 ].…”

Section: Regulatory T Cells In Myeloid Leukemiasmentioning

confidence: 99%

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Swatler

Turos-Korgul

Kozłowska

et al. 2021

Cancers

View full text Add to dashboard Cite

Both chronic myeloid leukemia and acute myeloid leukemia evade the immune response during their development and disease progression. As myeloid leukemia cells modify their bone marrow microenvironment, they lead to dysfunction of cytotoxic cells, such as CD8+ T cells or NK cells, simultaneously promoting development of immunosuppressive regulatory T cells and suppressive myeloid cells. This facilitates disease progression, spreading of leukemic blasts outside the bone marrow niche and therapy resistance. The following review focuses on main immunosuppressive features of myeloid leukemias. Firstly, factors derived directly from leukemic cells – inhibitory receptors, soluble factors and extracellular vesicles, are described. Further, we outline function, properties and origin of main immunosuppressive cells - regulatory T cells, myeloid derived suppressor cells and macrophages. Finally, we analyze interplay between recovery of effector immunity and therapeutic modalities, such as tyrosine kinase inhibitors and chemotherapy.

show abstract

Section: Regulatory T Cells In Myeloid Leukemiasmentioning

confidence: 99%

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Swatler

Turos-Korgul

Kozłowska

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Xu et al demonstrated that blocking the interaction between Tregs and AML cells may be a new approach to target leukemia stem cells in the treatment of AML [45]. ere was a higher proportion of CD4 + CD25 + CD127 − Foxp3 + Tregs in newly diagnosed AML patients than healthy controls [46]. All these findings manifested T cells involved in immune response and mediated progress of disease.…”

Section: Discussionmentioning

confidence: 99%

Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin

Piao

Wang

Pei

et al. 2022

Journal of Chemistry

View full text Add to dashboard Cite

Objective. The present study aimed at investigating the efficacy and safety of intravenous administration of cytarabine supplemented with idarubicin in treating acute myeloid leukemia (AML) patients undergoing first attack and its effects on serum levels of cell adhesion molecules, cytokines in response to inflammation, and T cell subset populations in acute myeloid leukemia (AML) patients undergoing first attack. Methods. A total of 88 AML patients eligible for inclusion and exclusion criteria participated in the study and were randomly assigned into the control group (n = 44) in which the patients received intravenous administration of cytarabine and daunorubicin and the study group (n = 44) in which the patients received intravenous administration of cytarabine and idarubicin. Clinical response, incidence of adverse reactions, and quality of life 3 months after therapy were evaluated. Soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), IL-10, and IL-35 were measured by ELISA methods. Phenotypic characteristics of T cell subsets including CD4+, CD8+, CD4+IL-10 Tregs, and CD4+CD25+CD127−Foxp3+ Tregs were analyzed by flow cytometry. Results. The clinical response rate of the study group was better than that of the control group (65.91% vs. 45.45%) ( P < 0.05 ). After treatment, the study group revealed significantly lower levels of sICAM-1, sVCAM-1, IL-10, and IL-35, a lower proportion of Tregs, a higher rate of CD4+/CD8+ T cells, along with increased scores of the Karnofsky Performance Scale (KPS) compared with the control group ( P < 0.05 ). The incidence rate of adverse reactions in the study group was lower than that in the control group (34.09% vs. 61.36%) ( P < 0.05 ). Conclusion. These findings demonstrate that intravenous administration of cytarabine supplemented with idarubicin can improve the immune function and quality of life of AML patients, and this combination drug therapy is effective and safe for AML.

show abstract

“…The proportion of macrophages was reported to be related to the survival and chemotherapy resistance of patients with AML [ 31 ]. Regulatory T cells were also revealed to play an important role in occurrence, progression, and immune response of AML [ 32 ]. In the present study, we first demonstrated a significant correlation between CDH23 expression and the infiltration level of various immune cells in AML.…”

Section: Discussionmentioning

confidence: 99%

Role of CDH23 as a prognostic biomarker and its relationship with immune infiltration in acute myeloid leukemia

Jiao

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background Cadherin-23 (CDH23) plays an important role in intercellular adhesion and is involved in the progression of several types of cancer. However, the biological functions and effect of CDH23 expression on the prognosis of patients with acute myeloid leukemia (AML) are unexplored. Herein, we aim to characterize the role and molecular functions of CDH23 in AML. Methods We downloaded the transcriptomic profiles and clinical data from the Cancer Genome Atlas and Beat AML trial. The expression level of CDH23 was assessed using Gene Expression Profiling Interactive Analysis (GEPIA). Kaplan-Meier survival analysis was used to assess prognostic value of CDH23. Correlation and biological function analyses were performed using LinkedOmics and GeneMANIA. Relationship of CDH23 with immune infiltration level was determined using Tumor Immune Estimation Resource (TIMER). Results We found that the CDH23 expression was aberrantly upregulated in patients with AML and could be used as an independent risk factor of overall survival using Cox multivariate analysis. Notably, we observed a negative correlation between CDH23 expression and immune cell infiltration abundance by calculating the immune and stromal scores. In addition, functional enrichment analysis established that CDH23 plays a crucial role in tumor immunity. Conclusions Our findings indicate that upregulated CDH23 expression corresponds to decreased overall survival of patients with AML. CDH23 may be involved in mediating tumor immune environment, and this highlights the potential of CDH23 as a therapeutic target in AML.

show abstract

Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia

Cited by 12 publications

References 31 publications

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin

Role of CDH23 as a prognostic biomarker and its relationship with immune infiltration in acute myeloid leukemia

Contact Info

Product

Resources

About